Showing results (111-120 of 125) with videos related to
Sort By:
Pageof 13
Chemical Biology & Drug Design|November 1, 2011
Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screenSen Zhang, Frank Wang, Jeffrey Keats, et al.Virchows Archiv : an International Journal of Pathology|September 12, 2020
Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from ChinaQianru Guo, Ning Liu, Frank Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothenedTracy Tang, Jean Y Tang, Dongwei Li, et al.Archives of Pathology & Laboratory Medicine|January 29, 2024
Eosinophilic Solid and Cystic Renal Cell Carcinoma: Morphologic and Immunohistochemical Study of 18 Cases and Review of the LiteratureQianru Guo, Xin Yao, Bo Yang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2014
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patientsAndrew P Garner, Joseph M Gozgit, Rana Anjum, et al.Bioorganic & Medicinal Chemistry Letters|August 12, 2008
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitorsYihan Wang, William C Shakespeare, Wei-Sheng Huang, et al.American Journal of Infection Control|November 26, 2015
Investigation of a cluster of Clostridium difficile infections in a pediatric oncology settingRaymund Dantes, Erin E Epson, Samuel R Dominguez, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical ModelsSen Zhang, Rana Anjum, Rachel Squillace, et al.Journal of Medicinal Chemistry|July 4, 2009
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluationWei-Sheng Huang, Xiaotian Zhu, Yihan Wang, et al.Cancer Cell|November 3, 2009
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceThomas O'Hare, William C Shakespeare, Xiaotian Zhu, et al.Pageof 13